Design Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Design Therapeutics Inc 's ROA in the second quarter of 2026?
Design Therapeutics Inc recorded a cumulative net loss of $-71 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -26.4%.

However, within the Healthcare sector 436 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3659, from total ROA ranking in the first quarter of 2026 at 4295.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	85.37 %	-3.45 %	-10.26 %	-19.12 %	-17.69 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-71	-70	-70	-67	-63
Return On Assets (TTM)	-26.4 %	-31.55 %	-31.3 %	-29.4 %	-26.25 %
DSGN's Total Ranking	# 3659	# 4295	# 3750	# 3705	# 3669
Total Assets (TTM) in million	410	228	225	210	221
Seq. Total Assets Change	79.82 %	1.38 %	6.96 %	-4.94 %	-6.34 %
Seq. Net Income Change	-	-	-	-	-

DSGN's 5 Years Annual ROA >> Back to DSGN Management Effectiveness >> Compare DSGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 169
Sector	# 437
Overall	# 3642

Return On Assets Statistics
High	Average	Low
-8.84 %	-20.95 %	-32.05 %
(Dec 31 2021)		(Jun 30 2026)

Financial Statements
Design Therapeutics Inc 's Assets	$ 410 million	DSGN's Balance sheet
Design Therapeutics Inc 's Income	$ -20 million	Quarterly DSGN's Income Statement
DSGN's Income by Division		See DSGN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-10.26 %	-13.12 %	-14.98 %	-12.37 %	-
Total Assets in million	225	250	288	339	387
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-70	-50	-67	-63	-36
Annual Return On Assets	-31.05 %	-19.8 %	-23.19 %	-18.67 %	-9.18 %

DSGN's 5 Years Annual ROA >> Back to DSGN Management Effectiveness >> Compare DSGN ROA to its Competitors

More Return On Assets Ratios
DSGN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DSGN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DSGN's Competitors
Subscribers only: Roa for Design Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for DSGN's Customers

You may also want to know
DSGN's Roi	DSGN's Inventory Turnover Ratio	DSGN's Growth Rates	DSGN's Dividend Comparisons
	DSGN's Profitability Ratios	DSGN's Asset Turnover Ratio	DSGN's Dividend Growth
DSGN's Roe	DSGN's Valuation Ratios	DSGN's Financial Strength Ratios	DSGN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T18:25:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.